https://ironwoodpharma.com/ironwood-pharmaceuticals-to-participate-in-upcoming-september-investor-conferences-4/ 2023-01-09T07:50:50-05:00 https://ironwoodpharma.com/ironwood-to-discontinue-iw-3718-development-program-following-results-from-planned-efficacy-assessment-2/ 2023-01-09T07:50:50-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-host-third-quarter-2020-investor-update-call-2/ 2023-01-09T07:50:50-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-appoints-alexander-denner-ph-d-to-board-of-directors-2/ 2023-01-09T07:50:50-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-reports-strong-third-quarter-2020-results-and-increases-full-year-2020-financial-guidance-2/ 2023-01-09T07:50:50-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-the-29th-annual-credit-suisse-healthcare-conference-2/ 2023-01-09T07:50:50-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-appoints-jay-p-shepard-to-board-of-directors-2/ 2023-01-09T07:50:50-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference-2/ 2023-01-09T07:50:50-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-host-fourth-quarter-and-full-year-2020-investor-update-call-2/ 2023-01-09T07:50:49-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-announces-ceo-transition-2/ 2023-01-09T07:50:49-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-reports-fourth-quarter-and-full-year-2020-results-exceeding-or-meeting-full-year-2020-financial-guidance-provides-full-year-2021-financial-guidance-2/ 2023-01-09T07:50:49-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-upcoming-investor-conferences-5/ 2023-01-09T07:50:49-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-host-first-quarter-2021-investor-update-call-2/ 2023-01-09T07:50:48-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-reports-first-quarter-2021-results-2/ 2023-01-09T07:50:48-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-announces-new-150-million-share-repurchase-program-2/ 2023-01-09T07:50:48-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-new-linaclotide-data-and-unveil-findings-from-gi-disease-surveys-at-digestive-disease-week-2021-2/ 2023-01-09T07:50:48-05:00 https://ironwoodpharma.com/more-than-a-third-of-surveyed-ibs-c-patients-reported-that-their-symptoms-worsened-during-covid-19-according-to-new-survey-findings-presented-by-ironwood-pharmaceuticals-at-digestive-disease-week-2/ 2023-01-09T07:50:48-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-announces-agreement-with-teva-involving-linzess-linaclotide-72-mcg-dosage-strength-2/ 2023-01-09T07:50:48-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-announces-leadership-updates-2/ 2023-01-09T07:50:48-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-announces-that-the-american-journal-of-gastroenterology-publishes-full-results-from-positive-linzess-linaclotide-phase-iiib-trial-in-adults-with-irritable-bowel-syndro-2/ 2023-01-09T07:50:48-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-host-second-quarter-2021-investor-update-call-2/ 2023-01-09T07:50:48-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-appoints-john-minardo-as-chief-legal-officer-2/ 2023-01-09T07:50:48-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-reports-strong-second-quarter-2021-results-raises-full-year-guidance-2/ 2023-01-09T07:50:48-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-announces-fda-approval-of-revised-linzess-linaclotide-label-2/ 2023-01-09T07:50:48-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-participate-in-upcoming-september-investor-conferences-3/ 2023-01-09T07:50:48-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-host-third-quarter-2021-investor-update-call-2/ 2023-01-09T07:50:47-05:00 https://ironwoodpharma.com/more-than-90-of-surveyed-ibs-c-patients-who-had-an-er-visit-or-hospitalization-in-the-past-year-identified-abdominal-pain-as-a-symptom-that-led-to-the-visit-according-to-data-announced-by-ironwood-p-2/ 2023-01-09T07:50:47-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-expands-pipeline-by-signing-an-option-agreement-to-acquire-an-exclusive-license-with-cour-pharmaceuticals-to-develop-and-commercialize-cnp-104-for-the-treatment-of-primary-b-2/ 2023-01-09T07:50:47-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-reports-third-quarter-2021-results-and-provides-corporate-development-update-2/ 2023-01-09T07:50:47-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-appoints-sravan-k-emany-as-chief-financial-officer-2/ 2023-01-09T07:50:46-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference-2/ 2023-01-09T07:50:46-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-provides-update-on-fy-2021-financial-guidance-and-announces-fy-2022-financial-guidance-2/ 2023-01-09T07:50:46-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-host-fourth-quarter-and-full-year-2021-investor-update-call-2/ 2023-01-09T07:50:46-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-reports-fourth-quarter-and-full-year-2021-results-linzess-linaclotide-achieves-blockbuster-status-as-u-s-net-sales-exceed-1-billion-in-2021-2/ 2023-01-09T07:50:46-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-upcoming-investor-conferences-4/ 2023-01-09T07:50:46-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-host-first-quarter-2022-investor-update-call-2/ 2023-01-09T07:50:46-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-reports-first-quarter-2022-results-maintains-full-year-2022-financial-guidance-2/ 2023-01-09T07:50:46-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-new-iw-3300-and-linaclotide-data-at-digestive-disease-week-2022-2/ 2023-01-09T07:50:46-05:00 https://ironwoodpharma.com/ironwood-presents-new-data-demonstrating-potential-of-iw-3300-for-visceral-pain-at-digestive-disease-week-ddw-2022-2/ 2023-01-09T07:50:46-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-host-second-quarter-2022-investor-update-call-2/ 2023-01-09T07:50:46-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-reports-second-quarter-2022-results-maintains-full-year-guidance-due-to-continued-strength-of-linzess-prescription-demand-2/ 2023-01-09T07:50:45-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-the-2022-wells-fargo-healthcare-conference-2/ 2023-01-09T07:50:45-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-reports-positive-topline-data-from-phase-iii-trial-of-linzess-linaclotide-in-pediatric-patients-aged-6-17-with-functional-constipation-3/ 2023-01-09T07:50:45-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-host-third-quarter-2022-investor-update-call-3/ 2023-01-09T07:50:45-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-reports-strong-third-quarter-2022-results-maintains-full-year-2022-financial-guidance-3/ 2023-01-09T07:50:45-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-participate-in-the-piper-sandler-34th-annual-healthcare-conference-3/ 2023-01-09T07:50:45-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference/ 2023-01-09T07:50:45-05:00 https://ironwoodpharma.com/david-ebersman-joins-ironwood-board-of-directors/ 2022-12-20T18:19:42-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-announces-second-quarter-2010-investor-update-call/ 2022-12-20T18:19:41-05:00 https://ironwoodpharma.com/almirall-and-ironwood-announce-positive-results-from-a-phase-3-trial-with-linaclotide-in-patients-with-irritable-bowel-syndrome-with-constipation/ 2022-12-20T18:19:41-05:00 https://ironwoodpharma.com/ironwood-and-forest-announce-positive-linaclotide-results-from-second-phase-3-trial-in-patients-with-irritable-bowel-syndrome-with-constipation/ 2022-12-20T18:19:40-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-provides-fourth-quarter-2010-investor-update/ 2022-12-20T18:19:40-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-j-p-morgan-healthcare-conference-2/ 2022-12-20T18:19:39-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-host-fourth-quarter-2012-investor-update-call/ 2022-12-20T18:19:36-05:00 https://ironwoodpharma.com/ironwood-and-actavis-to-present-linaclotide-data-at-the-american-college-of-gastroenterology-2014-annual-scientific-meeting/ 2022-12-20T18:19:33-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-initiates-phase-iii-trial-of-72-mcg-linaclotide-in-adult-patients-with-chronic-idiopathic-constipation/ 2022-12-20T18:19:32-05:00 https://ironwoodpharma.com/astellas-and-ironwood-report-positive-top-line-data-from-phase-iii-ibs-c-trial-conducted-in-japan/ 2022-12-20T18:19:29-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-details-strategy-to-build-top-performing-commercial-biotechnology-company/ 2022-12-20T18:19:29-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-host-fourth-quarter-and-full-year-2015-investor-update-call/ 2022-12-20T18:19:29-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-2016-rbc-capital-markets-global-healthcare-conference/ 2022-12-20T18:19:29-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-provides-fourth-quarter-and-full-year-2015-investor-update/ 2022-12-20T18:19:29-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-cowen-and-company-36th-annual-health-care-conference/ 2022-12-20T18:19:28-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-enters-into-u-s-licensing-agreement-with-astrazeneca-for-lesinurad/ 2022-12-20T18:19:28-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-j-p-morgan-healthcare-conference/ 2022-12-20T18:19:26-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-provides-second-quarter-2017-investor-update/ 2022-12-20T18:19:25-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-highlight-clinical-data-for-iw-3718-in-persistent-gastroesophageal-reflux-disease-gerd-at-digestive-disease-week-2018/ 2022-12-20T18:19:22-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-announces-chief-executive-officers-to-lead-ironwood-and-cyclerion-effective-upon-upcoming-separation/ 2022-12-20T18:19:21-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-and-allergan-initiate-patient-dosing-in-phase-ii-clinical-trial-of-md-7246-in-patients-with-abdominal-pain-associated-with-ibs-d/ 2022-12-20T18:19:20-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-establish-new-headquarters-in-downtown-boston/ 2022-12-20T18:19:20-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-the-28th-annual-credit-suisse-healthcare-conference/ 2022-12-20T18:19:19-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-appoints-sravan-k-emany-as-chief-financial-officer/ 2022-12-20T18:19:15-05:00 https://ironwoodpharma.com/ironwood-presents-new-data-demonstrating-potential-of-iw-3300-for-visceral-pain-at-digestive-disease-week-ddw-2022/ 2022-12-20T18:19:14-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-reports-second-quarter-2022-results-maintains-full-year-guidance-due-to-continued-strength-of-linzess-prescription-demand/ 2022-12-20T18:19:14-05:00 https://ironwoodpharma.com/abbvie-submits-supplemental-new-drug-application-to-u-s-fda-to-support-new-indication-of-linzess-linaclotide-for-functional-constipation-in-children-and-adolescents-6-to-17-years-of-age/ 2023-01-09T07:50:45-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-participate-in-the-piper-sandler-34th-annual-healthcare-conference-2/ 2022-12-20T18:19:14-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-reports-strong-third-quarter-2022-results-maintains-full-year-2022-financial-guidance-2/ 2022-12-20T18:19:14-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-host-third-quarter-2022-investor-update-call-2/ 2022-12-20T18:19:14-05:00 https://ironwoodpharma.com/microbia-and-forest-laboratories-announce-preliminary-results-of-linaclotide-phase-2b-studies/ 2022-12-20T18:19:43-05:00 https://ironwoodpharma.com/microbia-appoints-halley-gilbert-as-vice-president-general-counsel/ 2022-12-20T18:19:43-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-the-2022-wells-fargo-healthcare-conference/ 2022-12-20T18:19:14-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-reports-positive-topline-data-from-phase-iii-trial-of-linzess-linaclotide-in-pediatric-patients-aged-6-17-with-functional-constipation-2/ 2022-12-20T18:19:14-05:00 https://ironwoodpharma.com/microbia-announces-name-change-to-ironwood-pharmaceuticals/ 2022-12-20T18:19:43-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-and-forest-laboratories-announce-presentation-of-linaclotide-phase-2b-chronic-constipation-study-results/ 2022-12-20T18:19:43-05:00 https://ironwoodpharma.com/ironwood-and-forest-to-present-positive-data-from-linaclotide-phase-2b-ibs-c-study-at-acg-annual-scientific-conference/ 2022-12-20T18:19:43-05:00 https://ironwoodpharma.com/ironwood-raises-50-million-to-advance-linaclotide-through-phase-3/ 2022-12-20T18:19:43-05:00 https://ironwoodpharma.com/ironwood-and-collaborators-present-preclinical-data-demonstrating-that-cyclic-gmp-alleviates-intestinal-pain/ 2022-12-20T18:19:43-05:00 https://ironwoodpharma.com/ironwood-and-forest-present-positive-phase-2b-study-results-for-linaclotide-in-patients-with-irritable-bowel-syndrome-with-constipation/ 2022-12-20T18:19:43-05:00 https://ironwoodpharma.com/ironwood-presents-positive-phase-2b-study-results-for-linaclotide-in-patients-with-irritable-bowel-syndrome-with-constipation/ 2022-12-20T18:19:43-05:00 https://ironwoodpharma.com/ironwood-announces-linaclotide-european-licensing-agreement-with-almirall/ 2022-12-20T18:19:42-05:00 https://ironwoodpharma.com/ironwood-and-forest-to-present-additional-phase-2b-data-for-novel-gastrointestinal-agent-linaclotide/ 2022-12-20T18:19:42-05:00 https://ironwoodpharma.com/ironwood-and-forest-present-additional-positive-phase-2b-study-results-for-linaclotide-in-patients-with-irritable-bowel-syndrome-with-constipation/ 2022-12-20T18:19:42-05:00 https://ironwoodpharma.com/ironwood-appoints-thomas-mccourt-as-chief-commercial-officer-and-senior-vice-president-of-marketing-and-sales/ 2022-12-20T18:19:42-05:00 https://ironwoodpharma.com/marsha-fanucci-joins-ironwood-board-of-directors/ 2022-12-20T18:19:42-05:00 https://ironwoodpharma.com/ironwood-and-forest-announce-positive-linaclotide-results-from-two-pivotal-phase-3-trials-in-patients-with-chronic-constipation/ 2022-12-20T18:19:42-05:00 https://ironwoodpharma.com/ironwood-and-astellas-announce-japan-licensing-agreement-for-linaclotide/ 2022-12-20T18:19:42-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-files-registration-statement-for-initial-public-offering/ 2022-12-20T18:19:42-05:00 https://ironwoodpharma.com/underwriters-exercise-over-allotment-option-for-ironwood-pharmaceuticals-initial-public-offering/ 2022-12-20T18:19:42-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-files-annual-report-on-form-10-k/ 2022-12-20T18:19:42-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-announces-first-quarter-2010-investor-update-call-and-upcoming-presentation-at-bank-of-america-merrill-lynch-2010-health-care-conference/ 2022-12-20T18:19:42-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-provides-first-quarter-2010-investor-update/ 2022-12-20T18:19:41-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-announces-participation-in-j-p-morgan-biotech-ceo-cfo-conference-call/ 2022-12-20T18:19:41-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-announces-upcoming-presentation-at-wedbush-life-sciences-mac-best-ideas-2010/ 2022-12-20T18:19:41-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-provides-second-quarter-2010-investor-update/ 2022-12-20T18:19:41-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-announces-upcoming-presentation-at-morgan-stanley-global-healthcare-conference/ 2022-12-20T18:19:41-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-announces-conference-call-to-discuss-positive-linaclotide-phase-3-ibs-c-results-2/ 2022-12-20T18:19:41-05:00 https://ironwoodpharma.com/ironwood-and-forest-announce-positive-linaclotide-results-from-phase-3-trial-in-patients-with-irritable-bowel-syndrome-with-constipation/ 2022-12-20T18:19:41-05:00 https://ironwoodpharma.com/almirall-and-ironwood-announce-positive-results-from-the-second-phase-3-trial-of-linaclotide-in-patients-with-irritable-bowel-syndrome-with-constipation/ 2022-12-20T18:19:41-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-announces-conference-call-to-discuss-positive-linaclotide-phase-3-ibs-c-results/ 2022-12-20T18:19:40-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-provides-third-quarter-2010-investor-update/ 2022-12-20T18:19:40-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-announces-upcoming-presentation-at-credit-suisse-2010-healthcare-conference/ 2022-12-20T18:19:40-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-announces-upcoming-presentation-at-j-p-morgan-healthcare-conference/ 2022-12-20T18:19:40-05:00 https://ironwoodpharma.com/ironwood-and-protagonist-establish-collaboration-for-peptide-drug-discovery-and-development/ 2022-12-20T18:19:40-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-host-fourth-quarter-2010-investor-update-call/ 2022-12-20T18:19:40-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-announces-upcoming-presentation-at-cowen-and-company-annual-health-care-conference/ 2022-12-20T18:19:40-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-announces-upcoming-presentation-at-bank-of-america-merrill-lynch-2011-health-care-conference/ 2022-12-20T18:19:40-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-host-first-quarter-2011-investor-update-call/ 2022-12-20T18:19:39-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-provides-first-quarter-2011-investor-update/ 2022-12-20T18:19:39-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-announces-upcoming-presentations-at-jefferies-global-healthcare-conference-and-goldman-sachs-annual-global-healthcare-conference/ 2022-12-20T18:19:39-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-and-depomed-announce-collaboration-research-and-license-agreement/ 2022-12-20T18:19:39-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-host-second-quarter-2011-investor-update-call/ 2022-12-20T18:19:39-05:00 https://ironwoodpharma.com/ironwood-and-forest-announce-submission-of-new-drug-application-for-linaclotide-for-the-treatment-of-irritable-bowel-syndrome-with-constipation-and-chronic-constipation/ 2022-12-20T18:19:39-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-wedbush-securities-2011-life-sciences-management-access-conference/ 2022-12-20T18:19:39-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-provides-second-quarter-2011-investor-update/ 2022-12-20T18:19:39-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-morgan-stanley-global-healthcare-conference-5/ 2022-12-20T18:19:39-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-jefferies-2011-global-healthcare-conference/ 2022-12-20T18:19:39-05:00 https://ironwoodpharma.com/ironwood-announces-linaclotide-european-regulatory-submission-for-the-treatment-of-irritable-bowel-syndrome-with-constipation/ 2022-12-20T18:19:39-05:00 https://ironwoodpharma.com/ironwood-and-forest-announce-linaclotide-new-drug-application-for-the-treatment-of-irritable-bowel-syndrome-with-constipation-and-chronic-constipation-accepted-for-fda-review/ 2022-12-20T18:19:39-05:00 https://ironwoodpharma.com/ironwood-and-forest-to-present-linaclotide-results-from-phase-2b-and-phase-3-trials-in-patients-with-irritable-bowel-syndrome-with-constipation-or-chronic-constipation/ 2022-12-20T18:19:39-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-host-third-quarter-2011-investor-update-call/ 2022-12-20T18:19:39-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-credit-suisse-2011-healthcare-conference/ 2022-12-20T18:19:39-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-provides-third-quarter-2011-investor-update/ 2022-12-20T18:19:39-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-and-bionomics-announce-collaboration-research-and-license-agreement/ 2022-12-20T18:19:39-05:00 https://ironwoodpharma.com/ironwood-announces-fda-advisory-committee-meeting-will-not-be-scheduled-in-connection-with-new-drug-application-for-linaclotide/ 2022-12-20T18:19:39-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-announces-proposed-public-offering-of-common-stock-3/ 2022-12-20T18:19:38-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-prices-public-offering-of-common-stock-3/ 2022-12-20T18:19:38-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-announces-exercise-of-over-allotment-option-in-public-offering-of-common-stock/ 2022-12-20T18:19:38-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-host-fourth-quarter-2011-investor-update-call/ 2022-12-20T18:19:38-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-cowen-and-company-annual-health-care-conference/ 2022-12-20T18:19:38-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-provides-fourth-quarter-2011-investor-update/ 2022-12-20T18:19:38-05:00 https://ironwoodpharma.com/ironwood-and-forest-announce-fda-has-extended-the-review-period-for-linaclotide-to-september-2012/ 2022-12-20T18:19:38-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-host-first-quarter-2012-investor-update-call/ 2022-12-20T18:19:38-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-provides-first-quarter-2012-investor-update/ 2022-12-20T18:19:38-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-bank-of-america-merrill-lynch-2012-health-care-conference/ 2022-12-20T18:19:38-05:00 https://ironwoodpharma.com/ironwood-and-forest-to-present-17-linaclotide-related-abstracts-at-digestive-disease-week-2012/ 2022-12-20T18:19:38-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-upcoming-investor-conferences-3/ 2022-12-20T18:19:37-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-host-second-quarter-2012-investor-update-call/ 2022-12-20T18:19:37-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-provides-second-quarter-2012-investor-update/ 2022-12-20T18:19:37-05:00 https://ironwoodpharma.com/ironwood-and-forest-announce-fda-approval-of-linzess-linaclotide-for-the-treatment-of-irritable-bowel-syndrome-with-constipation-and-chronic-idiopathic-constipation/ 2022-12-20T18:19:37-05:00 https://ironwoodpharma.com/ironwood-and-forest-to-host-conference-call-to-discuss-fda-approval-of-linzess-linaclotide-for-the-treatment-of-irritable-bowel-syndrome-with-constipation-and-chronic-idiopathic-constipatio/ 2022-12-20T18:19:37-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-the-morgan-stanley-global-healthcare-conference/ 2022-12-20T18:19:37-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-the-ubs-global-life-sciences-conference/ 2022-12-20T18:19:37-05:00 https://ironwoodpharma.com/linaclotide-receives-positive-chmp-opinion-for-the-treatment-of-ibs-c/ 2022-12-20T18:19:37-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-host-third-quarter-2012-investor-update-call/ 2022-12-20T18:19:37-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-provides-third-quarter-2012-investor-update/ 2022-12-20T18:19:37-05:00 https://ironwoodpharma.com/ironwood-and-astrazeneca-announce-linaclotide-collaboration-for-china/ 2022-12-20T18:19:37-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-host-webinar-on-accounting-treatment-for-linzess-linaclotide/ 2022-12-20T18:19:36-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-the-credit-suisse-2012-healthcare-conference/ 2022-12-20T18:19:36-05:00 https://ironwoodpharma.com/constella-linaclotide-approved-in-europe-for-the-treatment-of-irritable-bowel-syndrome-with-constipation-ibs-c-in-adults/ 2022-12-20T18:19:36-05:00 https://ironwoodpharma.com/protagonist-and-ironwood-expand-peptide-drug-discovery-collaboration/ 2022-12-20T18:19:36-05:00 https://ironwoodpharma.com/ironwood-and-forest-announce-u-s-availability-of-linzess-linaclotide/ 2022-12-20T18:19:36-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-j-p-morgan-healthcare-conference-9/ 2022-12-20T18:19:36-05:00 https://ironwoodpharma.com/ironwood-completes-175-million-debt-offering/ 2022-12-20T18:19:36-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-provides-fourth-quarter-2012-investor-update/ 2022-12-20T18:19:36-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-promotes-dr-mark-currie-to-senior-vice-president-chief-scientific-officer-and-president-of-rd/ 2022-12-20T18:19:36-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-cowen-and-company-33rd-annual-health-care-conference/ 2022-12-20T18:19:36-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-appoints-edward-owens-to-board-of-directors/ 2022-12-20T18:19:36-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-host-first-quarter-2013-investor-update-call/ 2022-12-20T18:19:36-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-provides-first-quarter-2013-investor-update/ 2022-12-20T18:19:36-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-bank-of-america-merrill-lynch-2013-health-care-conference/ 2022-12-20T18:19:36-05:00 https://ironwoodpharma.com/ironwood-and-forest-to-present-linaclotide-data-at-digestive-disease-week-2013/ 2022-12-20T18:19:36-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-announces-proposed-public-offering-of-common-stock-2/ 2022-12-20T18:19:36-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-prices-public-offering-of-common-stock-2/ 2022-12-20T18:19:36-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-announces-partial-exercise-of-underwriters-option-in-public-offering-of-common-stock/ 2022-12-20T18:19:36-05:00 https://ironwoodpharma.com/constella-linaclotide-the-first-approved-prescription-therapy-in-a-new-class-of-treatments-for-adults-with-ibs-c-is-now-available-in-europe/ 2022-12-20T18:19:35-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-host-second-quarter-2013-investor-update-call/ 2022-12-20T18:19:35-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-provides-second-quarter-2013-investor-update/ 2022-12-20T18:19:35-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-appoints-dr-michael-hall-as-senior-vice-president-of-clinical-development/ 2022-12-20T18:19:35-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-morgan-stanley-global-healthcare-conference-4/ 2022-12-20T18:19:35-05:00 https://ironwoodpharma.com/ironwood-and-astrazeneca-initiate-linaclotide-phase-iii-trial-in-china-for-adults-with-ibs-c/ 2022-12-20T18:19:35-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-host-third-quarter-2013-investor-update-call/ 2022-12-20T18:19:35-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-provides-third-quarter-2013-investor-update/ 2022-12-20T18:19:35-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-credit-suisse-2013-healthcare-conference/ 2022-12-20T18:19:35-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-host-investor-day-on-december-12-2013/ 2022-12-20T18:19:35-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-details-strategy-to-establish-leading-gastrointestinal-therapeutics-company/ 2022-12-20T18:19:34-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-j-p-morgan-healthcare-conference-8/ 2022-12-20T18:19:34-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-host-fourth-quarter-2013-investor-update-call/ 2022-12-20T18:19:34-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-announces-alignment-of-workforce-with-priority-growth-platforms/ 2022-12-20T18:19:34-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-provides-fourth-quarter-2013-investor-update/ 2022-12-20T18:19:34-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-leerink-global-healthcare-conference/ 2022-12-20T18:19:34-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-announces-proposed-public-offering-of-common-stock/ 2022-12-20T18:19:34-05:00 https://ironwoodpharma.com/ironwood-receives-notice-of-allowance-for-methods-of-use-formulation-patent-expected-to-extend-linzess-patent-protection-through-2031/ 2022-12-20T18:19:34-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-prices-public-offering-of-common-stock/ 2022-12-20T18:19:34-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-appoints-julie-mchugh-to-board-of-directors/ 2022-12-20T18:19:34-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-announces-exercise-of-underwriters-option-in-public-offering-of-common-stock/ 2022-12-20T18:19:34-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-present-at-cowen-and-company-34th-annual-health-care-conference/ 2022-12-20T18:19:33-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-initiates-phase-ii-clinical-study-of-iw-3718-in-refractory-gastroesophageal-reflux-disease/ 2022-12-20T18:19:33-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-to-host-first-quarter-2014-investor-update-call/ 2022-12-20T18:19:33-05:00 https://ironwoodpharma.com/ironwood-and-forest-launch-new-direct-to-consumer-awareness-campaign-for-linzess/ 2022-12-20T18:19:33-05:00 https://ironwoodpharma.com/ironwood-pharmaceuticals-provides-first-quarter-2014-investor-update/ 2022-12-20T18:19:33-05:00 https://ironwoodpharma.com/ironwood-and-forest-to-present-linaclotide-data-at-digestive-disease-week-2014/ 2022-12-20T18:19:33-05:00